MOTS-c Analogues

The pharmacological problem with MOTS-c is not what it does but how briefly it does it — circulating levels fall back to baseline within a few hours, making a therapeutic regimen impractical. Analogue programmes therefore modify the parent 16-mer to slow clearance: substituting the residues most vulnerable to protease cleavage, adding D-amino acids or non-natural residues, N-terminal acetylation and C-terminal amidation, or conjugating to fatty acids for albumin binding in the way GLP-1 analogues do. There is also genuine polymorphism biology here: the K35R variant, common in Japanese populations, alters the MOTS-c sequence and has been associated with differences in exercise-related traits and longevity, which is why it is often mentioned alongside deliberately engineered analogues even though it is a naturally occurring variant rather than a drug. Downstream signalling is assumed to match native MOTS-c, but that assumption has been tested for very few of these variants.

Targets: AMPK, Folate–methionine one-carbon cycle, Proteolytic stability of the parent peptide

• · This is a category, not a specific product. Anything sold under this name should be treated with particular suspicion — if a vendor cannot tell you the exact sequence modification, you have no idea what is in the vial, and dosing a peptide of unknown structure at native-MOTS-c doses could give you a substantially larger effective exposure if the modification actually works.

Work out your exact syringe units →

• commonUnknown — profile depends entirely on the specific modification— There is no single safety profile for a category of undefined molecules.
• commonInjection-site irritation— Expected of the parent peptide and likely of the analogues.
• uncommonExaggerated or prolonged effects from unknown potency— The direct consequence of dosing a longer-acting analogue as though it were the short-acting parent.

• Type 1 diabetes or insulin use without glucose monitoring — inherited from the parent peptide's effect on glucose uptake, and potentially amplified by longer exposure.
• Pregnancy and breastfeeding — no data.
• Any product whose exact sequence modification the vendor cannot specify.

• redundantmots-c — Identical mechanism; running an analogue alongside native MOTS-c stacks the same pathway twice.
• redundantmetformin — Converging AMPK activation, as with the parent peptide.

• · Fasting glucose and HbA1c, as with native MOTS-c.
• · Third-party purity and identity testing matters more here than for almost anything else in this class, because the identity of the molecule is the open question.

Not approved anywhere; sold, when sold at all, as an ill-defined research chemical.

• Reynolds et al. 2021, Nature Communications — MOTS-c pharmacokinetics and the case for improved analogues (preclinical)
• Zempo et al., MOTS-c K35R polymorphism and exercise/longevity phenotypes in Japanese cohorts (other)

The pharmacological problem with MOTS-c is not what it does but how briefly it does it: circulating levels fall back toward baseline within a few hours, which makes a therapeutic regimen impractical. Analogue development therefore targets residence time rather than potency, using the standard peptide-engineering toolkit — substituting protease-vulnerable residues, incorporating D-amino acids or non-natural residues, capping the termini by acetylation and amidation, and conjugating fatty acids so the molecule rides on albumin the way semaglutide does. Downstream signalling is assumed to match the parent — folate-methionine cycle inhibition, AICAR accumulation, AMPK activation, and the CK2 binding identified in 2024 — but that assumption has been verified for very few variants, and it is not a safe assumption: the CK2 work showed that a single natural substitution, K14Q, is enough to abolish binding and lose the protective muscle phenotype. That finding is the most important thing to understand about this category, and it cuts both ways. It proves the sequence matters at single-residue resolution, which means an engineered substitution can silently destroy the activity you are paying for. And the natural variant biology is genuinely interesting in its own right: the m.1382A>C polymorphism producing K14Q is common in East Asian populations and has been associated with muscle fibre composition, sprint and power performance in men, and with appendicular muscle mass and grip strength in older Korean adults. That is real human association data — for a naturally occurring variant, in people who inherited it. It is not evidence for anything you can inject.

The failure mode is structural rather than incidental: you are buying a category, not a compound. If a vendor cannot tell you the exact sequence modification, you do not know what is in the vial, and every downstream decision — dose, frequency, expected duration, interaction risk — is unanchored. The specific danger is the inverse of what people assume. A successful stability modification means more effective exposure per milligram, not less, so dosing an undefined analogue at native-MOTS-c doses could give you a substantially larger effective exposure than you intend. The frequency error compounds it: native MOTS-c protocols are daily because the parent clears in hours, and running a genuinely long-acting analogue on that schedule stacks doses on top of each other. The second structural problem, and this is the one the 2024 CK2 work exposes, is that a single residue substitution is enough to abolish activity — the natural K14Q variant loses CK2 binding and loses the phenotype. So an engineered analogue might be more stable and completely inactive, and you would have no way to tell. Third, the K35R designation that circulates in vendor copy and community discussion is wrong. A 16-residue peptide has no residue 35. The documented natural variant is K14Q, from the mitochondrial m.1382A>C polymorphism. If a product page says K35R, that is a signal about how carefully the vendor reads the literature. Fourth, lipidated variants may be less soluble and need gentle warming to dissolve, and people mistake incomplete dissolution for a bad batch or, worse, inject a suspension of undissolved peptide.

1. 1 mgFirst week — 1 mg, well below any native MOTS-c dose. The entire logic of a stability modification is that it increases exposure per milligram — a successful analogue delivers more drug-time than the parent at the same mass. Starting at a native-peptide dose of 5-10 mg assumes the modification does not work, which is a strange thing to pay for. Check fasting glucose daily.
2. 2.5 mgWeek two, if week one was uneventful — 2.5 mg. Hold here for at least a week. With an unknown half-life you cannot rule out accumulation across daily doses, and if the analogue is genuinely long-acting, daily dosing inherited from the native protocol is the wrong frequency entirely.
3. 5 mgWeek three onward — 5 mg is the bottom of the native MOTS-c range and is a reasonable ceiling for an undefined analogue. Going beyond it means exceeding the parent-peptide dose with a molecule engineered to last longer, which has no rationale. This ladder is a harm-reduction structure invented for this record, not a validated schedule — none exists.

• Casein kinase 2 (CK2) — Direct binding demonstrated for wild-type MOTS-c; the K14Q variant shows reduced binding.

  Assumed to be preserved in engineered analogues, but the K14Q result shows a single residue change can abolish it. Any analogue that has not been tested for CK2 binding has an unverified primary mechanism.

• Folate-methionine one-carbon cycle — Pathway-level inhibition, inherited from the parent.

  AICAR accumulation leading to AMPK activation. Assumed rather than demonstrated for most analogues.

• AMPK (indirect) — No direct binding.

  Glucose uptake, fatty acid oxidation, mitochondrial biogenesis signalling — the metabolic phenotype the class exists to sustain for longer than the parent can.

• Proteolytic stability (the engineering target, not a biological one) — Not applicable.

  The whole point of the class. And the thing that makes an undefined analogue dangerous to dose at parent-peptide doses: a successful stability modification means more exposure per milligram, not less.

Unknown, and unknowable without knowing the specific modification, which is the point. A fatty-acid-conjugated albumin-binding analogue would be expected to behave like a once-weekly drug; a D-substituted variant might last hours to a day; a single point substitution might behave almost exactly like the parent. These are not variations on a timeline, they are different drugs. Anything presented as a definite onset schedule for 'MOTS-c analogues' as a class is invented.

The one stacking rule that matters here is not to run an analogue alongside native MOTS-c. Same mechanism, same pathway, and if the analogue is genuinely longer-acting you are layering sustained exposure on top of pulsed exposure with no way to estimate the total. Metformin is the same redundancy question as with the parent — converging AMPK activation, with the added problem that a long-acting analogue makes the overlap continuous rather than intermittent. The interaction that becomes materially more serious with a long-acting variant is with insulin, sulfonylureas and GLP-1 agonists: native MOTS-c's glucose-lowering effect is short and self-limiting, and an analogue engineered to last longer removes exactly that safety margin. If you are on any glucose-lowering agent, this category is not a reasonable thing to experiment with. Beyond that, the honest guidance is that you cannot give stacking advice for an undefined molecule, and anyone who does is making it up.

Against native MOTS-c: the parent has published discovery biology in Cell Metabolism and Nature Communications, a verified sequence, an identified protein partner, and human polymorphism data. An undefined analogue has none of that, plus an unknown identity. On evidence, the parent wins decisively; the only argument for an analogue is the pharmacokinetic one, and it is an argument you cannot verify has been delivered. Against GLP-1 analogues, which are the model this class is imitating: semaglutide's fatty acid conjugation was developed, characterised and tested through phase 3 with published pharmacokinetics at every step. That is what a successful peptide stabilisation programme looks like, and it is the standard against which 'stabilised MOTS-c' should be judged — nothing in this category is remotely close. Against SS-31: an approved drug with a label versus a category of undefined molecules. Against everything else on this site: this is the entry where the honest recommendation is the most straightforward. If you want MOTS-c biology, buy native MOTS-c with a verified sequence and accept the short half-life. Buying an unspecified modification is paying more for less information.

Not estimable and deliberately left null. Pricing varies with the specific modification — D-amino acid incorporation and fatty acid conjugation are substantially more expensive to synthesise than a single point substitution — and since the category has no defined member, there is no coherent cost to quote. A product priced identically to native MOTS-c is, if anything, weak evidence that no expensive modification was performed.

• ?No pharmacokinetic parameter has been published for any engineered MOTS-c analogue in humans or animals that I could locate.
• ?No engineered analogue has been through a human trial.
• ?Whether downstream signalling — folate cycle inhibition, AMPK activation, CK2 binding — is preserved has been tested for very few variants, and the K14Q result shows single substitutions can abolish it.
• ?The K35R designation widely used in vendor material and community discussion appears to be incorrect; the documented natural variant is K14Q from m.1382A>C. I could find no literature for a K35R MOTS-c variant, and a 16-residue peptide cannot have a residue 35. The Core record carries the K35R designation and should be read with this correction.
• ?The titration ladder in this record is a harm-reduction structure invented for this entry because no validated schedule exists for any analogue. It is explicitly not derived from data.
• ?Whether any product sold under this name has actually been modified at all is unverifiable without independent mass spectrometry.
• ?Blood-brain barrier penetration, accumulation behaviour and steady-state kinetics are unknown for every variant.
• ?Cost cannot be estimated because the category has no defined member.

• MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C, Nature Communications, 2021 · PMID 33473109

  Establishes the exercise-induction kinetics of endogenous MOTS-c that define the pharmacokinetic problem the analogue programmes exist to solve.

• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 Kumagai H, Kim SJ, Miller B, et al., iScience, 2024 · PMID 39559755

  The single most important paper for this category. The K14Q variant shows reduced CK2 binding and loses the protective phenotype — direct evidence that a single residue substitution can silently destroy MOTS-c activity. This is why an unspecified 'modified MOTS-c' is a genuine gamble rather than a marginal one.

• The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance Kumagai H, Natsume T, Kim SJ, et al., Biochimica et Biophysica Acta - General Subjects, 2022 · PMID 34728329

  The East Asian-specific m.1382A>C variant producing K14Q, associated with fast-twitch fibre predominance and sprint/power performance in men. The source of the naturally occurring variant biology that gets discussed alongside engineered analogues — and the correct designation, K14Q rather than K35R.

• The relationship between MOTS-c K14Q polymorphism and sarcopenia, blood lipids, and mental health in older Korean adults Kim S, Biomedicines, 2024 · PMID 39457696

  A second independent human cohort on the same variant — C allele carriers showed higher appendicular skeletal muscle mass and grip strength in older men. Strengthens the case that MOTS-c sequence matters functionally in people.

• MOTS-c, the most recent mitochondrial derived peptide in human aging and age-related diseases Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC, International Journal of Molecular Sciences, 2022 · PMID 36233287

  Review covering the parent peptide's biology and the case for improved analogues, with the parent sequence stated.